Elicio Therapeutics reports Q3 results (ELTX:NASDAQ)

Elicio Therapeutics reported Q3 net loss per share of $0.30, down from $0.60 year-over-year. R&D expenses fell 3% to $4.9M, while G&A expenses rose 18.5% to $3.6M. Total operating expenses increased 5.1% to $8.5M, and net loss narrowed 20.9% to $8.0M. The company had $30.9M in cash at Q3's end.

Original reporting
Published Nov 6, 2026, 10:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 10:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ELTX
Neutral
medium confidence
Mentioned
$ELTX
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ELTXNeutralMed
01

Why it matters

The earnings beat on loss metrics could attract short‑term buying interest, but the overall loss and cash position keep risk elevated.

02

Market read

First‑time Q3 earnings disclosure for ELTX with modest loss improvement; limited but actionable for traders in micro‑cap biotech space.

03

What to watch

R&D spend decreased while G&A rose, indicating potential cost‑structure shifts.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

Elicio Therapeutics is a Nasdaq‑listed biotech focused on early‑stage therapeutics.

Company-level read

Ticker impact

$ELTXNeutralMedium confidence
Context

Q3 earnings release showing narrowed net loss and improved loss per share.

Expected impact

potential slight upside as market prices in improved loss metrics

Evidence & confidence

Loss per share improved from $0.60 to $0.30 and net loss fell 20.9%, but the company remains loss-making with modest cash balances.

Market effects

Biotech sector may see slight positive sentiment from a loss improvement at a micro‑cap.

Limited to U.S. small‑cap biotech investors.

Minimal global impact.

Counterpoint

Despite the loss narrowing, the company still reports a net loss and may face cash runway concerns.

Key entities

  • Elicio Therapeutics

    Biotech firm reporting Q3 results.

Related articles

$ELTXHigh

Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • AMPLIFY-7P Phase 2 pre-specified analyses demonstrate substantial reductions in risk of recurrence or death in ctDNA negative patients and patients without prior radiation, enabling a

$ELTXHighAI 8/10

Elicio’s pancreatic cancer vaccine misses primary endpoint

Elicio Therapeutics (ELTX) reported that its Phase 2 study of camupepimut for pancreatic cancer did not meet the primary endpoint of disease-free survival. The study had a hazard ratio of 0.85, missing the target. Subgroup analyses showed potential benefits in patients without baseline ctDNA positivity. The company plans to discuss findings with the FDA for a potential Phase 3 study.

$ELTXMedAI 9/10

99% of evaluable treated patients showed immune responses to a cancer mutation. The trial missed its main goal.

Elicio Therapeutics (ELTX) reported Phase 2 trial results for camupepimut (ELI-002 7P) in pancreatic cancer, missing the primary DFS endpoint but showing favorable trends in subgroups. Key findings: 99% of patients showed immune responses, and DFS improvements were observed in ctDNA-negative (HR 0.51) and ctDNA-positive (HR 0.57) patients. The company plans to discuss Phase 3 study design with the FDA.

$ELTXLow

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an a